文献速递肾小球疾病

局灶节段性肾小球硬化

Focal Segmental Glomerulosclerosis.
PubMed 文献 · Clin J Am Soc Nephrol · 2017-02-27

本文综述局灶节段性肾小球硬化(FSGS)的病因分类、诊断评估与治疗选择。原发性FSGS推测由血浆因子所致,对免疫抑制治疗有反应且肾移植后可能复发;适应性FSGS与肾单位负荷过重相关;另有高外显率遗传性、病毒相关、药物相关及APOL1风险等位基因相关FSGS。肾活检与基因检测有助于病因识别,从而指导治疗与判断预后。

要点

  • 原发性FSGS推测由血浆因子所致,对免疫抑制治疗有反应,肾移植后存在复发风险。
  • 适应性FSGS与肾单位负荷过重相关,包括体型增大、肾单位容量减少或单个肾小球高滤过。
  • 已识别的高外显率遗传性FSGS涉及近40个基因中的某一个突变。

核心结论

  • 原发性FSGS推测由血浆因子所致,对免疫抑制治疗有反应且肾移植后存在复发风险。
  • FSGS病因包括原发性、适应性、高外显率遗传性、病毒相关、药物相关及APOL1风险等位基因相关等类别。
  • 识别FSGS病因可指导治疗选择并提供预后信息。
  • 尚待解决的问题包括原发性FSGS血浆因子的身份、常规基因检测的价值以及更有效且毒性更低的干预措施。

研究设计与样本

  • 本文为综述,检索范围原文未报告。

主要发现

  • 原发性FSGS推测由血浆因子所致,对免疫抑制治疗有反应,肾移植后存在复发风险。
  • 适应性FSGS与肾单位负荷过重相关,原因包括体型增大、肾单位容量减少或某些疾病相关的单个肾小球高滤过。
  • 高外显率遗传性FSGS由近40个基因中某一个的突变所致。
  • 新近识别病毒相关FSGS与药物相关FSGS为FSGS的病因。
  • 新出现的数据支持将APOL1风险等位基因相关FSGS列为第六类,见于撒哈拉以南非洲 ancestry 个体。

关键数值与推荐

  • 肾活检光镜线索包括肾小球大小、FSGS组织学变异型、微囊性小管改变及小管肥大。
  • 免疫荧光用于排除其他原发性肾小球病。
  • 电镜线索包括足细胞足突消失程度、足细胞微绒毛转化及管状网状包涵体。
  • 全面评估肾脏组织学有助于确定节段性肾小球硬化的实质背景,并将FSGS与其他肾小球疾病相关的FSGS区分开。
  • 基因检测在特定临床情形下有益。

临床怎么用

  • 特定FSGS患者的分类依赖临床病史、实验室检查、肾活检及部分患者基因检测结果的整合。
  • 识别FSGS病因可指导治疗选择并提供预后信息。

局限性

  • 原发性FSGS血浆因子的身份尚未明确。
  • 常规实施基因检测的价值尚待确定。
  • 尚需识别更有效且毒性更低的FSGS干预措施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Focal segmental glomerulosclerosis (FSGS) is a leading cause of kidney disease worldwide. The presumed etiology of primary FSGS is a plasma factor with responsiveness to immunosuppressive therapy and a risk of recurrence after kidney transplant-important disease characteristics. In contrast, adaptive FSGS is associated with excessive nephron workload due to increased body size, reduced nephron capacity, or single glomerular hyperfiltration associated with certain diseases. Additional etiologies are now recognized as drivers of FSGS: high-penetrance genetic FSGS due to mutations in one of nearly 40 genes, virus-associated FSGS, and medication-associated FSGS. Emerging data support the identification of a sixth category: APOL1 risk allele-associated FSGS in individuals with sub-Saharan ancestry. The classification of a particular patient with FSGS relies on integration of findings from clinical history, laboratory testing, kidney biopsy, and in some patients, genetic testing. The kidney biopsy can be helpful, with clues provided by features on light microscopy (e.g, glomerular size, histologic variant of FSGS, microcystic tubular changes, and tubular hypertrophy), immunofluorescence (e.g, to rule out other primary glomerulopathies), and electron microscopy (e.g., extent of podocyte foot process effacement, podocyte microvillous transformation, and tubuloreticular inclusions). A complete assessment of renal histology is important for establishing the parenchymal setting of segmental glomerulosclerosis, distinguishing FSGS associated with one of many other glomerular diseases from the clinical-pathologic syndrome of FSGS. Genetic testing is beneficial in particular clinical settings. Identifying the etiology of FSGS guides selection of therapy and provides prognostic insight. Much progress has been made in our understanding of FSGS, but important outstanding issues remain, including the identity of the plasma factor believed to be responsible for primary FSGS, the value of routine implementation of genetic testing, and the identification of more effective and less toxic therapeutic interventions for FSGS.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Rosenberg AZ, Kopp JB. Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol. 2017. PMID: 28242845. doi:10.2215/CJN.05960616

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。